Fortress Biotech Inc (FBIO)

Currency in USD
1.8200
-0.0300(-1.62%)
Closed·
After Hours
1.82000.0000(0.00%)
·
FBIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
FBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.81001.8700
52 wk Range
1.32502.3600
Key Statistics
Prev. Close
1.85
Open
1.87
Day's Range
1.81-1.87
52 wk Range
1.325-2.36
Volume
115.3K
Average Volume (3m)
203.09K
1-Year Change
-2.67%
Book Value / Share
0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.0000
Upside
+449.45%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Fortress Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Fortress Biotech Inc Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company’s early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Employees
101

Fortress Biotech Inc Earnings Call Summary for Q4/2024

  • Journey Medical reported a net loss of $14.7M in Q4 2024, with annual revenue declining to $56.1M from $59.7M in 2023
  • FDA-approved rosacea treatment IMROCI launched, targeting $1B market; expected to drive growth with meaningful revenue from Q2 2025
  • SG&A expenses reduced by 8% to $40.2M through optimization efforts; company maintained positive non-GAAP adjusted EBITDA
  • 2025 financial guidance delayed; focus on achieving peak payer coverage and exploring international licensing opportunities
  • CEO confident in IMROCI's potential, citing clinical superiority and favorable safety profile within current dermatology commercial model
Last Updated: 26/03/2025, 22:32
Read Full Transcript

Compare FBIO to Peers and Sector

Metrics to compare
FBIO
Peers
Sector
Relationship
P/E Ratio
−1.1x−3.1x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
2.4x2.7x2.6x
Price / LTM Sales
0.9x9.2x3.3x
Upside (Analyst Target)
-360.8%43.5%
Fair Value Upside
Unlock0.8%6.8%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.0000
(+449.45% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.48 / -0.12
Revenue / Forecast
13.14M / 22.24M
EPS Revisions
Last 90 days

FBIO Income Statement

People Also Watch

4.040
BTAI
+18.48%
37.72
EXEL
+0.88%
2.56
INMB
-8.24%
4.130
ATAI
-0.48%
0.032
NCNA
-3.05%

FAQ

What Stock Exchange Does Fortress Biotech Trade On?

Fortress Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Fortress Biotech?

The stock symbol for Fortress Biotech is "FBIO."

What Is the Fortress Biotech Market Cap?

As of today, Fortress Biotech market cap is 53.82M.

What Is Fortress Biotech's Earnings Per Share (TTM)?

The Fortress Biotech EPS (TTM) is -2.20.

From a Technical Analysis Perspective, Is FBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Fortress Biotech Stock Split?

Fortress Biotech has split 1 times.

How Many Employees Does Fortress Biotech Have?

Fortress Biotech has 101 employees.

What is the current trading status of Fortress Biotech (FBIO)?

As of 09 Aug 2025, Fortress Biotech (FBIO) is trading at a price of 1.82, with a previous close of 1.85. The stock has fluctuated within a day range of 1.81 to 1.87, while its 52-week range spans from 1.33 to 2.36.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.